Кристи Фанк - Грудь. Руководство пользователя [litres]

J. P. Pierce et al., “Greater Survival after Breast Cancer in Physically Active Women with High Vegetable-Fruit Intake Regardless of Obesity,” Journal of Clinical Oncology 25, no. 17 (2007): 2345–2351.

M. L. Irwin et al., “Influence of Pre- and Postdiagnosis Physical Activity on Mortality in Breast Cancer Survivors: The Health, Eating, Activity, and Lifestyle Study,” Journal of Clinical Oncology 26, no. 24 (2008): 3958–3964.

A. McTiernan et al., “Relation of BMI and Physical Activity to Sex Hormones in Postmenopausal Women,” Obesity 14, no. 9 (2006): 1662–1677.

J. F. Meneses-Echávez et al., “The Effect of Exercise Training on Mediators of Inflammation in Breast Cancer Survivors: A Systematic Review with Meta-analysis,” Cancer Epidemiology, Biomarkers and Prevention 25, no. 7 (2016): 1009–1017.

C. M. Dieli-Conwright and B. Z. Orozco, “Exercise after Breast Cancer Treatment: Current Perspectives,” Breast Cancer: Targets and Therapy 7 (2015): 353.

“Physical Activity and Your Heart: Recommendations for Physical Activity,” National Heart, Lung, and Blood Institute, открыто 31 июля 2017 года, https://www.nhlbi.nih.gov/health/health-topics/topics/phys/recommend.

J. M. Beasley et al., “Meeting the Physical Activity Guidelines and Survival after Breast Cancer: Findings from the After Breast Cancer Pooling Project,” Breast Cancer Research and Treatment 131, no. 2 (January 2012): 637–643.

B. MacMahon et al., “Age at First Birth and Breast Cancer Risk,” Bulletin of the World Health Organization 43, no. 2 (1970): 209–221.

B. MacMahon, “Reproduction and Cancer of the Breast,” Cancer 71, no. 10 (1993): 3185–3188.

P. Bruzzi et al., “Short Term Increase in Risk of Breast Cancer after Full Term Pregnancy,” British Medical Journal 297, no. 6656 (October 1988): 1096–1098.

B. MacMahon et al., “Age at First Birth and Breast Cancer Risk,” Bulletin of the World Health Organization 43, no. 2 (1970): 209–221.

B. MacMahon et al., “Age at First Birth and Breast Cancer Risk,” Bulletin of the World Health Organization 43, no. 2 (1970): 209–221.

Y. Zhou et al., “Association between Breastfeeding and Breast Cancer Risk: Evidence from a Meta-analysis,” Breastfeeding Medicine 10, no. 3 (2015): 175–182.

P. A. Newcomb, “Lactation and Breast Cancer Risk,” Journal of Mammary Gland Biology and Neoplasia 2, no. 3 (1997): 311–318; S. Y. Lee et al., “Effect of Lifetime Lactation on Breast Cancer Risk: A Korean Women’s Cohort Study,” International Journal of Cancer 105, no. 3 (June 2003): 390–393; J. L. Freudenheim et al., “Lactation History and Breast Cancer Risk,” American Journal of Epidemiology 146, no. 11 (December 1997): 932–938.

F. Islami, et al., “Breastfeeding and Breast Cancer Risk by Receptor Status – a Systematic Review and Meta-analysis,” Annals of Oncology 26, no. 12 (2015): 2398 – 4 07.

J. Kotsopoulos et al., “Breastfeeding and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers,” Breast Cancer Research 14, no. 2 (2012): R42.

G. Brignone et al., “A Case-Control Study on Breast Cancer Risk Factors in a Southern European Population,” International Journal of Epidemiology 16, no. 3 (September 1987): 356–361; E. Negri et al., “Lactation and the Risk of Breast Cancer in an Italian Population,” International Journal of Cancer 67, no. 2 (July 1996): 161–164; S. J. London et al., “Lactation and Risk of Breast Cancer in a Cohort of US Women,” American Journal of Epidemiology 132, no. 1 (July 1990): 17–26.

J. Russo et al., “17-Beta-estradiol Induces Transformation and Tumorigenesis in Human Breast Epithelial Cells,” The FASEB Journal 20, no. 10 (2006): 1622–1634.

B. T. Zhu and A. H. Conney, “Functional Role of Estrogen Metabolism in Target Cells: Review and Perspectives,” Carcinogenesis 19, no. 1 (1998): 1–27.

A. McTiernan et al., “Estrogen-Plus-Progestin Use and Mammographic Density in Postmenopausal Women: Women’s Health Initiative Randomized Trial,” Journal of the National Cancer Institute 97, no. 18 (September 2005): 1366–1376.

J. E. Rossouw et al., “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women’s Health Initiative Randomized Controlled Trial,” Journal of the American Medical Association 288, no. 3 (July 2002): 321–333.

Million Women Study Collaborators, “Breast Cancer and Hormone-Replacement Therapy in the Million Women Study,” The Lancet 362, no. 9382 (2003): 419–427.

G. Heiss et al., “Health Risks and Benefits 3 Years after Stopping Randomized Treatment with Estrogen and Progestin,” Journal of the American Medical Association 299, no. 9 (2008): 1036–1045.

V. Beralet et al., “Breast Cancer Risk in Relation to the Interval between Menopause and Starting Hormone Therapy,” Journal of the National Cancer Institute 103, no. 4 (2011): 296–305.

W. Y. Chen et al., “Unopposed Estrogen Therapy and the Risk of Invasive Breast Cancer,” Archives of Internal Medicine 166, no. 9 (2006): 1027–1032.

J. E. Manson et al., “Estrogen Therapy and Coronary-Artery Calcification,” New England Journal of Medicine 356 (June 2007): 2591–2602.

T. M. Brasky et al., “Specialty Supplements and Breast Cancer Risk in the Vitamins and Lifestyle (VITAL) Cohort,” Cancer Epidemiology, and Biomarkers and Prevention 19, no. 7 (2010): 1696–1708; C. L. Loprinzi et al., “Venlafaxine in Management of Hot Flashes in Survivors of Breast Cancer: A Randomised Controlled Trial,” The Lancet 356, no. 9247 (2000): 2059–2063.

A. Chang et al., “The Effect of Herbal Extract (EstroG‐100) on Pre‐, Peri‐ and Post‐menopausal Women: A Randomized Double‐Blind, Placebo‐Controlled Study,” Phytotherapy Research 26, no. 4 (2012): 510–516.

J. V. Pinkerton and G. D. Constantine, “Compounded Non-FDA – Approved Menopausal Hormone Therapy Prescriptions Have Increased: Results of a Pharmacy Survey,” Menopause 23, no. 4 (2016): 359.

A. Fournieret et al., “Use of Different Postmenopausal Hormone Therapies and Risk of Histology-and Hormone Receptor-Defined Invasive Breast Cancer,” Journal of Clinical Oncology 26, no. 8 (2008): 1260–1268.

American Cancer Society, Cancer Prevention and Early Detection 2005 .

P. D. Terry and T. E. Rohan, “Cigarette Smoking and the Risk of Breast Cancer in Women: A Review of the Literature,” Cancer Epidemiology, Biomarkers and Prevention 11, no. 10 (October 2002): 953–971.

M. D. Gammon et al., “Cigarette Smoking and Breast Cancer Risk among Young Women (United States),” Cancer Causes and Control 9, no. 6 (December 1998): 583–590.

P. Reynolds, “Smoking and Breast Cancer,” Journal of Mammary Gland Biology and Neoplasia 18 (2013): 15–23; S. A. Glantz and K. C. Johnson, “The Surgeon General Report on Smoking and Health 50 Years Later: Breast Cancer and the Cost of Increasing Caution,” Cancer Epidemiology, Biomarkers and Prevention 23, no. 1 (January 2014): 37–46.

L. Dossus et al., “Active and Passive Cigarette Smoking and Breast Cancer Risk: Results from the EPIC Cohort,” International Journal of Cancer 134, no. 8 (2014): 1871–1888.

Y. Cui, A. B. Miller, and T. E. Rohan, “Cigarette Smoking and Breast Cancer Risk: Update of a Prospective Cohort Study,” Breast Cancer Research and Treatment 100, no. 3 (December 2006): 293–299.

P. Reynolds et al., “Active Smoking, Household Passive Smoking, and Breast Cancer: Evidence from the California Teachers Study,” Journal of the National Cancer Institute 96, no. 1 (2004): 29–37.

M. N. Passarelli et al., “Cigarette Smoking Before and After Breast Cancer Diagnosis: Mortality from Breast Cancer and Smoking-Related Diseases,” Journal of Clinical Oncology 34, no. 12 (April 2016): 1315–1322.

J. Russo et al., “Cancer Risk Related to Mammary Gland Structure and Development,” Microscopy Research and Technique 52, no. 2 (2001): 204–223.

M. R. Bonner et al., “Breast Cancer Risk and Exposure in Early Life to Polycyclic Aromatic Hydrocarbons Using Total Suspended Particulates as a Proxy Measure,” Cancer Epidemiology, Biomarkers and Prevention 14 (2005): 53–60.

R. A. Rudel et al., “Chemicals Causing Mammary Gland Tumors in Animals Signal New Directions for Epidemiology, Chemicals Testing, and Risk Assessment for Breast Cancer Prevention,” Cancer 109, no. 12 (2007): 2635–2666.

C. D. Land, “Radiation and Breast Cancer Risk,” Progress in Clinical Biological Research396 (1997): 115–124; E. Pukkala et al., “Breast Cancer in Belarus and Ukraine after the Chernobyl Accident,” International Journal of Cancer 119 (2006): 651–658.

M. Morin-Doody et al., “Breast Cancer Mortality after Diagnostic Radiography: Findings from the U.S. Scoliosis Cohort Study,” Spine 25 (2005): 2052–2063.

N. G. Hildreth, R. E. Shore, and P. M. Dvoretsky, “The Risk of Breast Cancer after Irradiation of the Thymus in Infancy,” New England Journal of Medicine 321, no. 19 (1989): 1281–1284.

S. L. Hancock, M. A. Tucker, and R. T. Hoppe, “Breast Cancer after Treatment of Hodgkin’s Disease,” Journal of the National Cancer Institute 85 (1993): 25–31; A. C. Aisenberg et al., “High Risk of Breast Carcinoma after Irradiation of Young Women with Hodgkin’s Disease,” Cancer 79 (1997): 1203–1210.

K. Deniz et al., “Breast Cancer in Women after Treatment for Hodgkin’s Disease,” The Lancet Oncology 4, no. 4 (April 2003): 207–214.

K. C. Oeffinger et al., “Breast Cancer Surveillance Practices among Women Previously Treated with Chest Radiation for a Childhood Cancer,” Journal of the American Medical Association 301, no. 4 (2009): 404–414.